Published in Circulation on July 07, 2003
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A (2006) 2.72
Redox signaling in cardiac myocytes. Free Radic Biol Med (2011) 1.62
Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure (2012) 1.55
Association of β-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail (2012) 1.55
Redox signaling in cardiovascular health and disease. Free Radic Biol Med (2013) 1.16
Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.01
Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev (2004) 0.93
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. FASEB J (2011) 0.84
Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial. Vasc Health Risk Manag (2007) 0.83
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med (2005) 12.03
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med (2012) 9.22
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem (2004) 5.00
Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A (2005) 4.13
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med (2006) 4.07
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol (2012) 3.56
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 3.48
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int (2011) 3.32
What is the role of beta-adrenergic signaling in heart failure? Circ Res (2003) 3.22
Update on myocarditis. J Am Coll Cardiol (2012) 3.12
A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat Methods (2005) 3.11
Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science (2010) 2.99
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol (2003) 2.84
Repair versus replacement of the aortic valve in active infective endocarditis. Eur J Cardiothorac Surg (2012) 2.78
Widespread receptivity to neuropeptide PDF throughout the neuronal circadian clock network of Drosophila revealed by real-time cyclic AMP imaging. Neuron (2008) 2.73
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ Res (2006) 2.66
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol (2009) 2.59
Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation (2003) 2.59
Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res (2004) 2.58
Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol (2002) 2.54
Gi protein activation in intact cells involves subunit rearrangement rather than dissociation. Proc Natl Acad Sci U S A (2003) 2.52
Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol (2008) 2.51
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation (2002) 2.38
Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature (2003) 2.38
Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med (2009) 2.28
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation (2005) 2.25
Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21
Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ Res (2006) 2.21
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J (2010) 2.12
Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation (2002) 2.10
Phytophthora infestans effector AVR3a is essential for virulence and manipulates plant immunity by stabilizing host E3 ligase CMPG1. Proc Natl Acad Sci U S A (2010) 2.07
A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol (2011) 2.07
Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation (2012) 2.07
Dynamics of receptor/G protein coupling in living cells. EMBO J (2005) 2.06
Analysis of receptor oligomerization by FRAP microscopy. Nat Methods (2009) 2.06
Intraaortic vegetations as a manifestation of infective endocarditis. N Engl J Med (2007) 2.06
Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest (2014) 2.06
RING plus STRING: papillary muscle repositioning as an adjunctive repair technique for ischemic mitral regurgitation. J Thorac Cardiovasc Surg (2007) 2.05
Predictors of outcome in patients with suspected myocarditis. Circulation (2008) 2.03
The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med (2005) 2.02
Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol (2003) 2.01
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2007) 1.99
Pulsatile venoarterial perfusion using a novel synchronized cardiac assist device augments coronary artery blood flow during ventricular fibrillation. Artif Organs (2014) 1.99
MicroRNA-24 regulates vascularity after myocardial infarction. Circulation (2011) 1.98
Fluorescent sensors for rapid monitoring of intracellular cGMP. Nat Methods (2006) 1.96
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol (2012) 1.94
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol (2010) 1.94
NPP1, a Phytophthora-associated trigger of plant defense in parsley and Arabidopsis. Plant J (2002) 1.93
Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol (2012) 1.93
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol (2012) 1.92
Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation (2011) 1.91
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90
Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol (2002) 1.89
Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med (2014) 1.89
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J (2012) 1.89
Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol (2010) 1.88
Phytotoxicity and innate immune responses induced by Nep1-like proteins. Plant Cell (2006) 1.88
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun (2012) 1.88
Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther (2002) 1.84
Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol (2003) 1.82
Determination of onset of sexual maturation and mating behavior by melanocortin receptor 4 polymorphisms. Curr Biol (2010) 1.82
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc Natl Acad Sci U S A (2012) 1.82
Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens (2011) 1.80
Interplay of Ca2+ and cAMP signaling in the insulin-secreting MIN6 beta-cell line. J Biol Chem (2005) 1.80
Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol (2002) 1.79